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sDITORIAL COMMENT
allot’s Tetralogy and Pregnancy
rognostication and Prophesy*
ohn S. Child, MD, FACC
os Angeles, California
he odyssey of a blue baby from cyanotic infant to acyanotic
dult is a fascinating one. The pioneering work of Dr. John
. Gibbon, Jr., in developing cardiopulmonary bypass
echnology was a springboard to the repair of complex
ongenital cardiovascular malformations (1). Over 50 years
f cardiovascular surgery has resulted in one of the most
mpressive rehabilitative events in history (2). The approx-
mate incidence of tetralogy of Fallot (TOF) of about 400
er million live births marks it as the most common
omplex or cyanotic defect (3). Corrective surgery for TOF
ow permits over 85% of such children to survive into
dulthood (4,5). Approximately 50% of patients with TOF
re women, and it was one of the first disorders to be
urgically palliated or repaired; as such, “repaired” tetralogy
s one of the most frequently encountered conditions in
regnant women (6,7).
See page 174
In the U.S., there is a preponderance of pregnant women
ith heart disease who are now found to have some form of
ongenital cardiovascular malformation, whether repaired,
orrected, palliated, or untreated (7). The circulatory and
espiratory physiology in the normal gravid state are well
nown (7–9). These hemodynamic alterations are com-
ounded in women with heart disease, at times with severe
onsequences. Pregnancy in cyanotic congenital heart de-
ects (even with Eisenmenger syndrome excluded) carries a
igh incidence of miscarriage, premature birth, and low
irth weights, the frequency of which increases with the
egree of maternal cyanosis, maternal complications, and
eed for anticoagulation (7,10–13). The potential pre-
ictors of maternal morbidity include: functional class,
entricular dysfunction, significant arrhythmias, cyanosis,
utflow tract obstruction, pulmonary hypertension, and
eed for anticoagulants (e.g., prosthetic valves) (8,11,12,14–
7).
In the modern era, systematic data on the outcomes of
regnancy in women with TOF, both those who underwent
urgery and those who did not, are few and far between.
herefore, it is fitting that a careful report of a large number
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Ahmanson-UCLA Adult Congenital Heart Disease Center, UCLA
ivision of Cardiology, Department of Medicine, David Geffen School of Medicinert UCLA, Los Angeles, California.f such patients, as appears in this issue of the Journal (18),
hould now come from an institution with a long history of
xcellent congenital cardiac surgery and with a program
evoted to the care of adult survivors with congenital heart
isease. At the time of this study from the Mayo Clinic,
hey had in their database 147 adult women (18 years old)
ith TOF, of which 17 had died (not related to pregnancy),
1 were lost to follow-up, and 2 were institutionalized for
evelopmental delay. Of the remaining 107 invited to
articipate, 72 responded to requests for follow-up infor-
ation. Of these 72, 43 had 112 pregnancies; 82 of these
12 pregnancies (73%) were successful.
Of the 43 women, 8 were unrepaired at the time of their
0 successful pregnancies; 5 of the 8 were cyanotic at the
ime of 12 pregnancies. In 20 (of the 43) patients (47%),
OF was initially palliated by some form of aortopulmonary
hunt. Ultimately, all patients had repair with ventricular
eptal defect closure and right ventricular (RV) outflow tract
epair. Among the 43 patients, 56% had patch reconstruc-
ion of the RV outflow tract, of which 40% were trans-
nnular, a pertinent precursor for future significant pulmo-
ary regurgitation. Among the 43 TOF patients with 112
regnancies, 16 patients had 30 miscarriages (27% rate), and
here was 1 stillbirth at term (18). Low infant birth weight
as related to the maternal state of women who had not
ndergone reparative surgery or to morphologic pulmonary
rtery abnormalities. Of the seven infants who were small
or gestational age, five (71%) were born to women with
ntreated TOF. Of the 30 pregnancy losses (in 16 women),
occurred in 2 women with unrepaired TOF.
The recurrence rate of congenital defects has historically
een difficult to determine with precision. A review of 6,640
onsecutive pregnancies evaluated by detailed fetal echocar-
iography reported it is at least 2.9% in maternal and 2.2%
n paternal congenital heart disease, greater in the case of
utflow tract defects (such as TOF) (7,19). Other studies
rovide estimates of incidence in live births to a parent with
ongenital heart disease ranging from 4.9% to 14% (10,20).
hese figures contrast with a spontaneous incidence rate
stimated at median of 7 per 1,000 live births (3). In the
eport by Veldtman et al. (18), five of the live infants (6%)
ad congenital abnormalities, none with TOF (one with
uscular ventricular septal defect; one with mitral prolapse;
ne with hypoplastic left heart syndrome; one with pyloric
tenosis; and one with cleft lip/palate, strabismus, and
lubbed feet). One mother incidentally had a documented
2q11 deletion syndrome, but this chromosomal abnormal-
ty was not systematically evaluated in this study.
Maternal cardiovascular complications were noted in six
14%) of the pregnant women: supraventricular tachycar-
ia in two, heart failure in two, pulmonary embolism in one
with pre-existing pulmonary hypertension), and progres-
ive RV dilation in one (with pre-existing severe pulmonary
egurgitation ) (18). Note that in one of the women with
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Editorial Comment July 7, 2004:181–3eart failure, it appeared to be “peri-partum” cardiomyop-
thy rather than related to her intrinsic TOF.
The mere relief of cyanosis, although a step forward for
he mother and fetus, does not guarantee that there may not
e serious issues to face in the pregnant woman with TOF
fter long-term follow-up of the postoperative milieu. Cures
n congenital heart surgery are few and far between. The
hallenges encountered by adults with repaired congenital
eart disease include major or minor residua (abnormalities
eft behind) or sequelae (abnormalities caused by surgery but
ot technically considered complications), which includes
lectrophysiologic issues, anatomic or functional ventricular
r valvular abnormalities, and/or prosthetic materials such
s patches, conduits, and valves (4,6,21,22).
Left ventricular dysfunction may be related to chronic
olume overload as a result of previous long-standing large
ortopulmonary shunts, to inadequate intraoperative myo-
ardial preservation, to significant aortic or mitral regurgi-
ation, or even to acquired diseases (e.g., systemic arterial
ypertension). Right heart dysfunction may relate to the
ize of RV outflow incisions and/or a patch or incisional
neurysm, residual or recurrent pulmonary stenosis or re-
urgitation, a large residual or recurrent ventricular septal
efect shunt, or pulmonary hypertension.
Prognostication suggests a knowledgeable look at the
tatus of a disease and prediction of outcome. The report by
eldtman et al. (18) is reassuring in that women with
ell-repaired TOF with no major residua or sequelae appear
t an overall low risk of morbidity from pregnancy. It bears
dding that even if there are no significant anatomic or
emodynamic issues at hand, the frequent presence of aortic
egurgitation or prosthetic valves and conduits warrants
rophylaxis against infective endocarditis at parturition
23,24). Furthermore, many have a dilated aortic root, in
art the result of an intrinsic or acquired tissue defect, which
ay be aggravated with the hemodynamic load of preg-
ancy (25–27).
Prophesy implies a future that is set but can be foretold or
ivined from the signs at hand. Because women with
urgically corrected TOF are now able to more successfully
onceive and bear children, and because an incidence of
ransmission from the affected mother well exceeds the
poradic event in the general population, the number of
OF patients will steadily increase with each coming year.
here is a strong need for carefully coordinated multidisci-
linary efforts to maintain long-term follow-up of such
ndividuals, and the recent 32nd Bethesda Conference
ddressed the issues in detail (13,28–30).
eprint requests and correspondence: Dr. John S. Child,
CLA Medical Center, Division of Cardiology, Room 47-123
HS, 650 Charles E. Young Drive South, Los Angeles, California
0095-0001. E-mail: jchild@mednet.ucla.edu.EFERENCES
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